Shots:

• Arbormentis to receive $51M upfront in cash and equity in addition to $150M as milestone related to pre-specified development and commercialization milestones along with royalties on any commercialized therapy resulting from the collaboration
• Relmada acquires the development & commercial rights for psilocybin and derivate program from Arbormentis in all Ex-Asia countries- including the US & EU. Additionally- companies collaborate to develop new therapies targeting neurological and psychiatric disorder
• Relmada’s REL-1017 is currently in P-III trial for depression & results is expected from the human abuse potential study for REL-1017 in July’21

  | Ref: PRNewswire | Image: Relmada